In a cross-sectional study of breast cancer, an analysis of stage I to III breast cancer patients who received NAC from 2018 to 2019 found that, in response to treatment, there was a significant association between complete response and FOXP1 (p = 0.01) [38]. This evidence concerns the gene FOXP1 and breast carcinoma.